

Date and Time: 29th November 2011, 10:30-16:30

Minutes: Confirmed

Hepatitis B GDG Meeting 3

Place: NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

Present: GDG

1. Howard Thomas (Chair)	HT
2. Elizabeth Boxall	EB
3. Javier Vilar	JV
4. Alan Mitchell – present for notes 1-7	AM
5. Geoffrey Dusheiko – present for notes 7-11	GD
6. Aftab Ala	AA
7. Emily Lam	EL
8. Steven Bradley	SB
9. Ashley Brown (Co-optee)	AB

NCGC Technical team

10. Gill Ritchie	GR
11. Grammati Sarri	GS
12. Rosa Lau	RL
13. Laura Sawyer	LS
14. Amy Kelsey	AK
15. Richard Whittome – present for notes 9-11	RW
16. Grant Hill-Cawthorne	GHC

NICE

17. Sarah Dunsdon	SD
-------------------	----

Apologies

18. Angela Narbey	AN
19. Gareth Tudor-Williams	GTW

Notes

1. The Chair welcomed the group to the Hepatitis B Guideline Development Group (GDG) meeting 3. Apologies were received from Angela Narbey and Gareth Tudor-Williams. The Chair welcomed Ashley Brown who has joined the GDG as a co-opted expert in paediatrics.
2. The Chair asked the GDG to declare if they had any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role).

JV declared a non-personal pecuniary interest: he is giving a talk on 30th November 2011 at the North of England Hepatitis B group. The meeting is supported by Gilead but the speakers are not receiving any payment as the talk is independent.

AA declared a non-personal pecuniary interest: he has received research grants from Roche and BMS for a hypothesis driven clinical research project looking at the prevalence and knowledge of viral hepatitis (hepatitis B and C) in the Surrey asian population. It specifically involves the use of dry blood spot testing in the setting of mosques. The research grant from Roche and BMS has been used to support a part time nurse and dry blood spot testing kits. He also declared a personal pecuniary interest: he has received support for travel expenses to AASLD meeting from Gilead and Roche.

AB declared a personal pecuniary interest: he has sat on advisory boards and received honoraria from Roche, Merck, Sharpe & Dome, Bristol Myers Squibb, Novartis, Gilead, Jansen and Sanofi-Pasteur. He also declared a personal pecuniary interest: he received support for attendance at conferences and clinical research from Roche, MSD, BMS, Novartis, Gilead, Jansen and Sanofi-Pasteur.

3. The Chair then briefed the group on the meetings objectives.
4. The Chair introduced Grammati Sarri, NCGC Senior Research Fellow, who gave a presentation on the clinical effectiveness of pharmacological monotherapies and combination therapies in achieving remission of the activity of CHB in children. The Chair thanked GS for her presentation.
5. The GDG then discussed the evidence presented and drafted 3 recommendations.
6. GS and Rosa Lau, NCGC Research Fellow, then gave a presentation on the clinical effectiveness of pharmacological combinations in achieving remission of the activity of CHB in adults. The GDG then discussed the evidence presented. The Chair thanked GS and RL for their presentation.
7. The Chair introduced Laura Sawyer, NCGC Senior Health Economist, who gave a presentation on the cost effectiveness of pharmacological combinations in achieving remission of the activity of CHB in adults. The GDG then discussed the evidence presented.
8. LS then gave a presentation to the GDG on the Economic Plan. The GDG then discussed the plan and agreed on the model outline. The Chair thanked LS for her presentations.
9. GS and RL then led discussion with the GDG on the research protocol for 1 clinical question. The protocol for monitoring tests was agreed and signed off by the GDG.
10. There was no other business to discuss. The Chair closed the meeting and thanked everyone for attending.

Notes

Date, time and venue of the next meeting

11. Tuesday 17th January 2012, 10:30-16:30, NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ.